Aditxt ( ($ADTX) ) just unveiled an announcement. On July 8, 2025, Amro Albanna, CEO of Aditxt, Inc., presented at Wall Street Reporter’s Next ...

As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering. The plan reflects Aditxt's broader vision to build a global, socially driven biotech platform ...

Aditxt ( (ADTX)) has issued an announcement. On June 26, 2025, Aditxt‘s CEO, Amro Albanna, presented at Wall Street Reporter’s Next Super Stock livestream event, discussing the company’s strategic ...

Prior to Evofem, Ms. Pelletier was Executive Director at Woman Care Global, an international nonprofit organization focused on creating sustainable supply chains to deliver reproductive healthcare ...

Evofem Biosciences retains ownership and continues its commercialization efforts, with annual revenues from PHEXXI sales exceeding $19 million in 2024.

Evofem expects PHEXXI COGS will decrease by 55% to 60% from current levels. Furthermore, there will be no cost to Evofem for the tech transfer to the new manufacturer engaged by Windtree.

Evofem expects PHEXXI COGS will decrease by 55% to 60% from current levels. Furthermore, there will be no cost to Evofem for the tech transfer to the new manufacturer engaged by Windtree.

Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT) ...

Evofem Reports Fourth Consecutive Year of Net Sales Growth Evofem Reports Fourth Consecutive Year of Net Sales Growth PR Newswire SAN DIEGO, March 24, 2025 -- 2024 Net Sales Increased 6% to $19.4 ...